6-Month, Multicenter, Randomized, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Antihyperglycemic Drugs
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EDITION AP
- Sponsors Sanofi
- 25 Sep 2020 Results of pooled analysis from NCT02855684; NCT01689142 and NCT01676220 assessing efficacy and safety of Gla-300 in East Asian population with type 2 diabetes, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 06 Dec 2019 Results presented at the 2019 Congress of the International Diabetes Federation
- 16 Aug 2018 Status changed from active, no longer recruiting to completed.